Novavax Soars 17.38% on FDA COVID-19 Vaccine Approval

On May 19, 2025, Novavax's stock surged by 17.38% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Novavax's recent stock surge can be attributed to the FDA's conditional approval of its COVID-19 vaccine. This approval targets specific populations under particular conditions, providing a much-needed boost to the company's market position and investor confidence.

The approval is a significant milestone for Novavax, as it validates the company's efforts in developing a COVID-19 vaccine. This development is expected to drive further growth and potentially open new opportunities for the biotechnology firm.

Novavax has been actively engaged in discussions with the FDA regarding the approval of its COVID-19 vaccine. These ongoing talks indicate the company's commitment to meeting regulatory standards and ensuring the safety and efficacy of its vaccine.